HER2-Low and HER2-Zero in Breast Cancer: Prognosis & Prediction | Oncotarget
Questions remaining in the field of HER2-low breast cancer
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
DESTINY-Breast04: practice-changing results for HER2-low breast cancer
ADCs for the treatment of HER2-low breast cancer
The evolution of HER2-low breast cancer from primary to recurrence
Overview of the management of HER2-low breast cancer patients
Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer Paradigm
Latest news in HER2-low breast cancer
Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in Review
The evolution of HER2-low-positive breast cancer as a clinical subtype
HER2-low is not a distinct subtype in inflammatory breast cancer
Novel treatment options for HER2-low breast cancer
The Science of HER2-low Breast Cancer and Implications for the Pathology Team
The exciting new field of HER2-low breast cancer
Remaining questions surrounding HER2-low breast cancer – how low can you go?
Remaining challenges regarding HER2-low breast cancer
Is HER2-low a distinct subtype of breast cancer?
Genomic and transcriptomic landscape of HER2-low breast cancer
HER2-low breast cancer: the ESMO Expert Consensus Statements